Personalized medicine that analyzes the DNA of tumors can eradicate cancer in up to a third of patients & # 39 ;, study claims
- The tumor of each patient is unique, without & # 39; one-size-fits-all & # 39; treatment
- Scientists looked at 215 people with a range of cancers that failed with existing drugs
- Were treated according to & # 39; molecular variants & # 39; on their specific tumor
Personalized medicine can eradicate cancer in a third of patients & # 39 ;, research suggests.
Each tumor is unique, and studies have increasingly shown that there is no & # 39; one-size-fits-all & # 39; approach to treating the disease.
However, there is limited evidence that the benefits of treating patients demonstrate the specific DNA of their cancer.
Scientists from the Netherlands Cancer Institute therefore looked at 215 people with different types of cancer who had not responded to existing medicines.
The patients were treated according to & # 39; molecular variants & # 39; on their specific tumor.
After 16 weeks, 74 (34 percent) saw their cancer disappear or shrink, the results show. The effects were still observed in 26 patients until two years later.
Personalized medicine can eradicate cancer in a third of patients & # 39; (stock)
One in two people born after 1960 in the UK will develop cancer at some point in their lives, according to statistics from Cancer Research UK.
People with the same & # 39; type & # 39; tumor can differ in the composition of the malignant mass, which can affect how they respond to treatment.
Analyzing the DNA of a specific tumor can cause variants on which existing drugs work, even if they are not approved for that specific disease, the scientists wrote in the journal Nature.
When patients take these drugs & # 39; off-label & # 39; the outcome is not always recorded, they added.
WHAT IS PERSONALIZED CANCER TREATMENT?
Personalized anti-cancer drugs are prescribed according to the specific DNA and the growth of a tumor.
Genetic testing of both malignant and healthy cells helps doctors adjust treatment.
This is usually more effective and reduces side effects.
Before a personalized treatment, most people with a specific type and stage of cancer received the same medicine.
Scientists noted that some patients responded better than others.
They therefore looked for genetic differences that could influence the success of the treatment.
Targeted treatments are available for the following forms of cancer:
- Multiple myeloma
- Some types of leukemia and lymphoma
- Some cancers in children
Some are only offered through clinical trials. They can also be expensive and time-consuming.
The scientists therefore created the Drug Rediscovery protocol, which monitors the outcome of a different drug for a specific tumor.
To test the effectiveness, they looked at 215 cancer patients with & # 39; useful variants for which no approved drugs are available & # 39 ;.
The patients had also exhausted or rejected all existing treatments.
After 16 weeks, 34 percent achieved a clinical or partial response.
A clinical response is that all cancers disappear without leaving a disease, while a partial response occurs when a tumor shrinks by a certain percentage.
One of these results occurred in 136 patients who received off-label targeted drugs and 79 in immunotherapy.
The benefits lasted an average of nine months, with 26 patients receiving a & # 39; ongoing clinical benefit & # 39; when the study ended in May this year.
Of the 141 (66 percent) patients who did not have & # 39; clinical benefit & # 39; 117 had progressive cancer.
Twenty-four did not complete the study due to death, side effects, or just a & # 39; preference & # 39; not to participate.
The scientists claim that the safety results were comparable to those in real situations.
They believe their research investigates the & # 39; feasibility of precision medicine driven by tumor type and profile & # 39; demonstrates.
The database can one day & # 39; more appropriate treatment options for each patient & # 39; said the team.
It can also be shared internationally for the benefit of patients around the world.
However, the scientists emphasize that the research is not a & # 39; control group & # 39; which limits its reliability.
. (TagsToTranslate) Dailymail (t) health